In the druggability evaluation, we found that drugs targeting SIRPA have been investigated in clinical trials for the treatment of cancers such as acute myeloid leukemia (evorpacept) and large B-cell lymphoma (maplirpacept) (Supplementary Table S7). Here, SIRPA is linked to acute myeloid leukemia.